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Successful Treatment of Orbital 
Lymphangioma with Intralesional 
Bleomycin and Application of Cont i­
n uous Negative Pressure
Dear Editor,
Recently, we experienced a case of pediatric orbital 
lymphangioma successfully treated with intralesional bleo-
mycin injection. To our knowledge, this is the first such case 
report in Korea of this treatment used for this condition. 
An 8-year-old male visited our clinic complaining of 
eyelid swelling and proptosis in his left eye for 5 days (Fig. 
1A and 1B). He was diagnosed with an external stye and 
was administered antibiotics 4 days ago, but showed no 
improvement. The best-corrected visual acuity of the left 
eye was 20 / 30 and intraocular pressure was 32 mmHg. 
The patient complained of severe subconjunctival hemor-
rhage and pain. Initial computed tomography (CT) and 
magnetic resonance (MR) images showed a 22.2 × 25.4 
mm-sized macrocystic lymphangioma in the left infero-
temporal orbit (Fig. 1C and 1D). 
An inferior lower eyelid incision was made to facilitate 
the approach to the macrocyst. An opening was made on 
the cystic wall and the internal wall of the cyst was ex-
posed using Sewall retractors. Blood evacuation was per-
formed with a suction catheter. Bleomycin (1 IU per milli-
liter saline) was injected into the cyst for exactly 5 minutes 
(Fig. 1E). Barovac (100 mL; Sewoon Medical, Seoul, Ko-
rea) was inserted into the cyst to provide continuous nega-
tive pressure to induce cyst shrinkage and reduce the risk 
of delayed or recurrent bleeding (Fig. 1F). On the third day 
after the operation, the visual acuity had returned to 20 / 
20, and intraocular pressure remained at 20 mmHg. At this 
point, 10 mg of prednisolone was administered for 2 weeks 
with a tapering schedule. At 1 month of follow-up, the pa-
tient’s symptoms and signs were completely resolved (Fig. 
1G and 1H). CT and MR imaging results showed no resid-
ual macrocystic lymphangioma, and there was no sign of 
re-bleeding (Fig. 1I and 1J). There were also no signs of re-
currence at 6 months of follow-up.
Lymphangioma is a congenital malformation of the lym-
phatic system that frequently occurs in the head and neck 
[1]. Orbital lymphangioma manifests in proptosis and re-
striction of ocular motility following minor trauma or up-
per respiratory tract infection. Its mass effect may lead to 
compressive optic neuropathy or exposure keratopathy. 
Surgery is considered when there are symptoms such as de-
creased visual acuity, amblyopia, and severe cosmetic dis-
figurement. However, complete resection of the lesion is 
difficult to achieve, increasing the risk of local recurrence 
and complications involving injury to surrounding struc-
tures. Multiple treatment modalities including radiotherapy, 
intralesional/oral corticosteroid and intralesional sclerosing 
therapy can be adopted in conjunction with surgery [1].
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Fig. 1. Images of the 8-year-old male patient admitted for macrocystic lymphangioma in the 
left orbit and imaging studies of the lesion. (A,B) Images of the patient on his first clinical 
visit presenting with swelling of the eyelid and conjunctiva, hyperemia and severe proptosis 
of the left eye. Computed tomography (C) and magnetic resonance T2 weighted (D) images 
of the lesion during the first clinical visit. A macrocystic lymphangioma (22.2 × 25.4 mm) 
was observed at the inferotemporal corner of the left orbit. (E) The lesion was approached via 
incision into the inferior lower eyelid and exposure of the cyst interior using Sewall retractor. 
Bleomycin (1 IU per milliliter saline) was injected inside the cystic wall. (F) Barovac was 
inserted inside the cyst to maintain continuous negative pressure. (G,H) Images taken during 
the follow-up one month after the surgery. The patient is symptom-free and is without any 
sign of local recurrence. (I,J) Computed tomography and magnetic resonance images during 
the follow-up one months after the surgery showed nearly absorved macrocystic lymphangio-
ma. Informed consent was received from parents of the patient.
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Intralesional sclerosing therapy is used to induce cyst 
collapse by destroying the epithelial lining of the cystic 
wall of macrocystic lymphangioma and by reducing lym-
phatic f luid production. OK-432 (Picibanil, Shuhei Ogita 
Fund, Japan), Sotradecol (sodium tetradecyl sulphate; Bi-
oniche Pharma, Galway, Ireland), sodium morrhuate and 
bleomycin are commonly used as sclerosing agents [2,3]. 
Bleomycin is a chemotherapeutic agent that generates free 
radicals to induce DNA strand scissions. It is often used in 
patients with vascular malformation such as lymphangio-
ma to cause sclerosis of vascular endothelium. Local injec-
tion of bleomycin shows a 72.3% success rate and compli-
cations such as erythema, edema and/or pain at the 
injection site have been reported [4]. Gooding and Meyer 
[5] injected bleomycin in 4 patients with orbital lymphan-
gioma, all of whom presented favorable clinical outcomes 
without systemic or ophthalmic complications.
The present case is the first in Korea to report the use of 
local bleomycin injection as a successful treatment modal-
ity for orbital lymphangioma. Postoperative follow-up 
showed improved visual acuity, intraocular pressure, and 
proptosis without complications such as pain, erythema 
and swelling. No sign of recurrence was observed follow-
ing a one-step surgery. The authors attribute the successful 
treatment to a number of factors that facilitated the sur-
gery. For example, incision into the cystic wall enabled 
bleomycin injection directly into the macrocyst. Further-
more, minimal exposure of the surrounding tissue to the 
drug reduced its side effects. Also, control of hemorrhage 
increased the therapeutic potential of the drug without di-
lution. Finally, barovac insertion into the cyst to control 
additional bleeding and maintain negative pressure effec-
tively induced cyst shrinkage. 
It is imperative that surgeons confirm the precise loca-
tion of the lesion, inject sclerosing agents for a specific pe-
riod of time, and apply continuous negative pressure to en-
sure cystic shrinkage for effective surgical outcome. A 
longer follow-up period is required to investigate the rate 
of local recurrence.
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